Interaction in COPD experiment (ICE): A hazardous combination of cigarette smoking and bronchodilation in chronic obstructive pulmonary disease

Medical Hypotheses

Volumn 74, Issue 2, 2010, Pages 277-280

  van Dijk, W D ^a   Heijdra, Y ^a   Scheepers, P T J ^a   Lenders, J W M ^a   van Weel, C ^a   Schermer, T R J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CARBON MONOXIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; NICOTINE; TAR;

ARTICLE; ASTHMA; BRONCHODILATATION; CARDIOVASCULAR DISEASE; CHRONIC DRUG ADMINISTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; HEALTH HAZARD; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; LUNG DEPOSIT; PATIENT EDUCATION; PRIORITY JOURNAL; RISK FACTOR; SMOKING CESSATION; SMOKING HABIT;

BRONCHODILATOR AGENTS; HUMANS; INCIDENCE; MODELS, BIOLOGICAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 72449129913     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.09.012     Document Type: Article

References (37)

1. GOLD executive committee, GOLD science committee. GOLD Guidelines; 2008 [accessed July 2009].
2. Curkendall S.M., Lanes S., de Luise C., Stang M.R., She D., and Goehring Jr. E. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur J Epidemiol 21 11 (2006) 803-813
3. Huiart L., Ernst P., and Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 128 4 (2005) 2640-2646
4. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 9438 (2004) 937-952
5. Fabbri L.M., and Rabe K.F. From COPD to chronic systemic inflammatory syndrome?. Lancet 370 9589 (2007) 797-799
6. Schermer T., Heijdra Y., Zadel S., et al. Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD. Respir Med 101 6 (2007) 1355-13562
7. Ellerbeck E.F., Mahnken J.D., Cupertino A.P., et al. Effect of varying levels of disease management on smoking cessation: a randomized trial. Ann Intern Med 150 7 (2009) 437-446
8. Sundblad B.M., Larsson K., and Nathell L. High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine Tob Res 10 5 (2008) 883-890
9. Teo K.K., Ounpuu S., Hawken S., et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 368 9536 (2006) 647-658
10. Doll R., Peto R., Boreham J., and Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 328 7455 (2004) 1519
11. Anthonisen N.R., Connett J.E., Kiley J.P., et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The lung health study. JAMA 272 19 (1994) 1497-1505
12. Godtfredsen N.S., Lam T.H., Hansel T.T., et al. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J 32 4 (2008) 844-853
13. Anthonisen N.R., Connett J.E., Enright P.L., and Manfreda J. Hospitalizations and mortality in the lung health study. Am J Respir Crit Care 166 3 (2002) 333-339
14. Spitzer W.O., Suissa S., Ernst P., et al. The use of beta-agonists and the risk of death and near death from asthma. New Engl J Med 326 8 (1992) 501-506
15. Sears M.R., and Taylor D.R. The beta2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Safety 11 4 (1994) 259-283
16. Taylor D.R., Sears M.R., Herbison G.P., et al. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax 48 2 (1993) 134-138
17. van Schayck C.P., Dompeling E., van Herwaarden C.L.A., et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomized controlled study. BMJ 303 (1991) 1426-1431
18. Dompeling E., van Schayck C.P., van Grunsven P.M., et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study [see comments]. Ann Intern Med 118 10 (1993) 770-778
19. Mullen M., Mullen B., and Carey M. The association between beta-agonist use and death from asthma. JAMA 270 15 (1993) 1842-1845
20. van Schayck C.P., Postma D.S., and Lammers J.W. The place of long-acting beta2 adrenergic agonists in the treatment of asthma and chronic obstructive lung disease (COPD). Ned Tijdschr Geneeskd 143 3 (1999) 137-140
21. Van Noord J.A., Aumann J.L., Janssens E., et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 129 3 (2006) 509-517
22. Appleton S., Poole P., Smith B., Veale A., Lasserson T.J., and Chan M.M. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev 3 (2006) CD001104
23. Jones P.W., Willits L.R., Burge P.S., and Calverley P.M. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 21 1 (2003) 68-73
24. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New Engl J Med 356 8 (2007) 775-789
25. Sin D.D., Wu L., Anderson J.A., et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 60 12 (2005) 992-997
26. Tashkin D.P., Celli B., Senn S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New Engl J Med (2008)
27. Rodrigo G.J., Castro-Rodriguez J.A., Nannini L.J., Moral V.P., and Schiavi E.A. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med (2009)
28. Salpeter S.R., Ormiston T.M., and Salpeter E.E. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 125 6 (2004) 2309-2321
29. Singh S., Loke Y.K., and Furberg C.D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300 12 (2008) 1439-1450
30. Feng S., Plunkett S.E., Lam K., et al. A new method for estimating the retention of selected smoke constituents in the respiratory tract of smokers during cigarette smoking. Inhal Toxicol 19 2 (2007) 169-179
31. Usmani O.S., Biddiscombe M.F., and Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care 172 12 (2005) 1497-1504
32. Chang P.-T., Peters L.K., and Ueno Y. Particle size distribution of mainstream cigarette smoke undergoing dilution. Aerosol Sci Technol 4 2 (1985) 191-207
33. Borgerding M., and Klus H. Analysis of complex mixtures-cigarette smoke. Exp Toxicol Pathol 57 Suppl. 1 (2005) 43-73
34. Iversen E.T., Sorensen T., Heckscher T., and Jensen J.I. Effect of terbutaline on exercise capacity and pulmonary function in patients with chronic obstructive pulmonary disease. Lung 177 4 (1999) 263-271
35. Invernizzi G., Boffi R., Ruprecht A., Barnes P.J., Kharitonov S.A., and Paredi P. Real-time measurement of particulate matter deposition in the lung. Biomarkers 11 3 (2006) 221-232
36. Ambrose J.A., and Barua R.S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 43 10 (2004) 1731-1737
37. Lee K.W., Hill J.S., Walley K.R., and Frohlich J.J. Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort. CMAJ 174 4 (2006) 461-466